† Independent biopharma research · est. 2025

Biopharma researchthat takes a position.

Each note connects disease biology, trial interpretation and financial analysis to a stated price and a stated invalidation.

48 notes published†50 company files†8 names under active coverage

§ 01

The publication — today’s product

Original research,
written to a thesis.

Every full note is stored as MDX and files its evidence into a growing company record, so the publication reads like a system rather than a feed.

View the complete research archive
Notes published
48
Full-text research library
Continuous coverage
7
Active publication months
Analytic layers
6
Per research note
Company records
50
JSON-backed profiles

Recent research

7 most recent

IVA

Nov 12, 2026 · Catalyst Preview

Even a MASH Win May Not Be Enough for Inventiva

Catalyst Setup · Valuation · MASH

Inventiva trades at €3.36 weeks before NATiV3, a 72-week Phase 3 that tests lanifibranor on the strictest histology endpoint in MASH. If the trial hits, how large do the composite and fibrosis gains need to be for the shares to be worth more than the price, and what does the financing do to the equity if it misses?

View the complete research archive
§ 02

Company intelligence — maintained files

The article ends.
The file keeps working.

Research is organized into living company records. Switch companies and the thesis, pipeline, catalysts, evidence and risks move together.

File MDGL · Updated Sep 10, 2026

Madrigal Pharmaceuticals

Metabolic / MASH
Clinaptis stanceNegativeMedium conviction

Commercial-stage hepatology company anchored by Rezdiffra, the first approved liver-directed therapy for adults with noncirrhotic MASH and F2–F3 fibrosis.

“Madrigal is executing exceptionally well, but MDGL increasingly prices first-mover leadership as durable ownership of a broad MASH market. Clinaptis sees Rezdiffra as an important bridge therapy after metabolic optimization and before more fibrosis-directed treatment.”
What matters mostWhether the durable Rezdiffra-addressable population remaining after GLP-1 optimization and before fibrosis-directed escalation can support the valuation-implied franchise.
§ 03

Coverage — deliberately asymmetric

A focused core.
A wider field of view.

Core names receive the deepest maintained work. The wider coverage index keeps the surrounding competitive and therapeutic context visible.

View the full coverage list
§ 04

From articles to intelligence

One body of knowledge, three stages

The publication, company files and connections are one accumulating research asset.

  1. Live

    Research articles

    Full-length notes, each with an explicit conclusion.

    48 published notes
  2. Expanding

    Company intelligence

    Thesis, assets, catalysts and risks in one maintained file.

    50 company files
  3. Planned

    Connected knowledge base

    New evidence updates the view without losing its reasoning.

    Article → Company → Asset → View
§ 05

Research approach — the method

How the desk
thinks.

Seven moves, applied to every note: biology before valuation, evidence before opinion, and each opinion paired with its exit condition.

“Say what matters to the stock, show the reasoning, and say what would change it.”
  1. 01
    Start with the question

    Scientific and investment questions first — never the press release.

  2. 02
    Understand the mechanism

    Receptor, pathway and disease context: why the biology could change practice.

  3. 03
    Evaluate the evidence

    Trial data and competing interpretations, weighed on a common frame.

  4. 04
    Connect to the economics

    What the science implies for revenue, cash flow and the balance sheet.

  5. 05
    Isolate what matters

    Name the one or two drivers that decide most of the stock.

  6. 06
    Define catalysts and killers

    The coming events — and the evidence that would end the thesis.

  7. 07
    Update as information arrives

    A living view, re-argued with each new filing and readout.